finds Thank call to you us. everyone, time. and be safe you, Greg. loved still I and excited uncertain this Good your joining We're with and all morning, thanks for hope you in today, ones
the excellence, with management toward or and first, also call advance on starting the from first prioritizing, disciplined clinic, therapy our discussed ophthalmic our milestones; our we towards this timely last our experience, morning team, management with our relevant advancing clinical begin sure to third, fiscally review preclinical our focus XXXX: a delivering members; gene we meaningful our second, for pipeline programs. foremost make strategic like a that bolstering data programs executing for but and operational Board this I'd and both of on X team regulatory in to eye with priorities operational
of X, assess midpoint the it's Priority XXXX, that we're doing. how let's Now accomplished.
to our specific We experience have operational management of added Board team Directors. our and
our we be And on management the Vishwas Board Research our of our our team of enhanced members. importantly, position appointment us to most Development. X level appointment noted Seshadri, QX Head new strengthened of from with with As joined call, at who a senior and Clinical we BMS Dr. the
BLA successful to teams addition, the In EB B experience and our even has Vish some paramount months. for been experience, our program regulatory which under strength we've added development X MPS. meetings for more and of relevant last over added clinical Type We've X
and the our to continue we quality BLA we Cleveland as technical to Also, move readiness team in fortify sets. skill closer operations
will far, we continue of XXXX All be been talent the in marketplace. about strengthened teams thus and adding have to best the opportunistic in these
Priority X, on target.
We have are achieving and significant clinical timely delivered excellence disciplined operational a in manner. delivering fiscally in and milestones
in start RDEB, our program pivotal Let's with EB-XXX.
driving excited a our the towards trial and a in site second to you progress made all tell in for we completing opening ultimately patient I'm registration BLA XXXX. about enrollment,
MPS I'm with meeting made A Type collaborative confirming the that the and FDA in about IIIA month, also we to Transpher on study IIIA. a successful which you progress pivotal MPS tell program, B ABO-XXX the for excited last had our is
X long-term the to and third approval. of follow We'll assess will conclusion for high-dose Our at and B study IIIB, be patients concluding program, MPS at continue level these specifically neurocognitive safety the over Cohort efficacy, enrollment clinical the development further to Transpher time. we are
priority And target. on also then X,
speed precision. toward programs clinic great and advancing the are We eye our preclinical with
primate results the we of QX, X reported studies. nonhuman During
with will be some concept of select this into We indications. XXXX year, ophthalmic proven second the study in begin on this studies are track and half enabling to toxicology
Now let's preclinical progress deeper dive clinical and take the of our programs. a programs into
or epidermolysis EB-XXX, dystrophic lead Phase for RDEB. Study our with VIITAL recessive III pivotal Starting bullosa,
Medical momentum We recently are patients pleased continue clinical professionals, VIITAL. Memorial continues health Worcester, enrollment at activated and and and and growing to and of under and have level very professional build There Mass principal expert, Dermatology. EB care of UMass a to site high in we to second investigator she in Medical Dr. trial Pediatric interest a at of among Director Dr. Wiss be Dermatology School, the world Karen Wiss. is Center Pediatrics renounced is UMass
chronic team are to mission Abeona's We standard for wounds. of excited UMass a RDEB and join have care large pursuing of
and the staff milestone, and you UMass. execution is team at to on congratulate major this This timely significant and I want to thank a and
in in for patients and addition family. provide Center Palo Now can logistics participants Alto, locations on for the lead East travel Medical West convenient Stanford site California, Coast, and easier we trial treatment both at making to study our
XXXX to I'll seems it our remind far, the the up and our in investment challenges 'XX, community, one this be from in we community was major pandemic. with thus heard of opening
The second to our site success. paramount is
for we same in time, the potential EB-XXX experience physician necessary At the we're U.S. launch plan commercial with expanding as
We clinical to They team subjects ready go. as in look enrolled soon forward to VIITAL in collaborating to are screen the possible. at closely UMass as the with
completing toward in continue enrollment patient we the Study. Next, our progress VIITAL
#X. EB-XXX administered to successfully have We patient
recall the new may to rebiopsy and patient from product. call, make our is you who this last As opted
their and extremely for happy The patient followed are of rebiopsy be and per as received report our have was will patient, that this to the product EB-XXX protocol. manufacturing EB-XXX administration. they VIITAL successful We
Additional and for to identified now continue be at their eligibility both prescreened determine Stanford and patients UMass VIITAL. to
than XX XX pivotal I'm wounds approximately excited the that trial across of more to target the reminder, of report patients. of pairs far. As for we have half to treated number thus XX chronic Today, of large is the wounds the target treatment a randomized
the our Next, Type Syndrome to A ABO-XXX, turn our MPS program, second our platform, disease. in-clinic let's IIIA attention or AAV Sanfilippo
meeting the FDA FDA course, a for with potentially MPS and license program. data the study pivotal we support Yesterday, meeting current a had biologic We the single-arm the B news with announced and the will serve study collaborative about set. very B our aligned depending of Type for that the Transpher ABO-XXX on application, some A exciting IIIA as Type successful
Since seen treated of trial. earlier reported patients magnitude XXXX, we our safety higher A we investigational ABO-XXX year. Symposium from the with dose benefits in the and in Transpher World younger the excited We're XX the this cohort have now as children about at the product the
with The remain Cohort We the focused effects displayed X could as pivotal delivering more They already similar packages recently evaluable of XXXX. if we in excellence on need. EB-XXX cannot now and in serve have presented, the wait unmet intent dosed now remain hopeful children tremendous have in those we X one data one for patients data set treatment ABO-XXX. XXXX, we for fully operational and that
Vish little that will Children. already in using At which meeting, shortly. to for B assessment is and you endpoint sequence. neurocognitive and align from Transpher scaled points. Kauffman primary be raw for the we development, A collecting move bit the in with we're These as also used Battery data is the primary more the This Type the toddler barely infant A, on score tell Transpher of scales FDA definition end the about Assessment a They will secondary the and will
bringing closely to to with to our their agency look goal with are afflicted of life-saving We the MPS patients toward potentially for FDA guidance, we the and forward grateful therapy work IIIA. to continuing
ex near plans other markets. the EMA, meeting we the U.S. for our future, potentially world share in In intend the B feedback authorities around MAA followed Type development the to with by guide regulatory to
the course, first Of United is States our focus.
front, regulatory an on past data addition before the oral and on presentation during also very from International In some and new clarity published this that the at to the the XXth encouraging guidance A had we data. MRI not FDA our related shared new Transpher diseases, weekend, Symposium MPS from clinical been
callosum gray and treatment. young indicates in months data the IIIA volumes without post to with amygdala patient compared brain that patients an ABO-XXX X afflicted The XX in increases at Corpus MPS treatment matter.
with physical about long-term disability. in Brain IIIA, Now moment. and for is it's volume a let's characteristic loss with this and cognitive talk associated children MPS
important is function amygdala and development, gray social Specifically, for cognitive callosum fear for corpus well matter as emotional for learning as and motor development.
with clinicians. followup. X in presented of the children that this consistent as we the X development younger -- A preservation of Cohort younger children neurocognitive have the our from in reported We're it's are earlier excited we MRI results that its about X along data, And Transpher with previously from year
Moving onward the study to ABO-XXX Transpher in for our IIIB. last B MPS in-clinic program,
and biomarkers the reported safe from clear high-dose eliciting results As last at results B The and effects. Symposium the sustained Transpher in Transpher Transpher reduction quarterly a drug A tolerated, B to noted show in dose-dependent, in biologic World high-dose the cohort date, cohort, February. call, disease-specific like on is well we the demoting
be biomarkers As moving want in we past, development collection direction. the into we the standard data, mature that absolutely see in right and to the I let will XXXX. of the But neurocognitive need you reminded to gold
the shared in accrual X-year Hospital X B its higher Nationwide Ohio, export. paused after was by in the because reached in again drug product, Transpher cohort patients we dosing the shelf Children's Previously, supplied had life
B met additional of for our were specifications Transpher of stability results parameters protocol. Some showed all not testing
However, specifically physical titer.
of the remaining the drug that infectious through of patients Health Germany The for treated DSMB, However, with profile use risk on those purity the families. outweighed need a well in Regulatory the the German and to test individuals program product along after with be titer, the reviewing Authority, drug, of request compassionate MPP name deem equivalent as physicians potency, endorsed unmet use allows is German the program. and results the the patient benefit based of as highest the our at treating their the that
patients. X the number the patients drug treatment. vector at per to times We're X getting To is of Transpher between total MPP and dosed thankful in the treated will XX and soon higher now X collectively. ready German a XX patients program authority to these genomes for Cohort the for quickly the to The acting fourth dose, actions get date, DSMB be B kilogram prescreened MPP have been and the and children now X
the process in the been Transpher rigor we're and both the study, main monitored closing parallel, within the B program enrollment will be have study. EB-XXX from with ongoing they efficacy B safety B the and same the Transpher as for Transpher patient high-dose in of and product patients the In would of use
in points. 'XX essential of promising, we these first next and cohort as While early preservation important of have We first Transpher gold for dosed development of in the data standard is seeing some half beginning we the patients X-year and neurocognitive the neurocognitive the look determine forward discussed. to are we'll B. data some steps from And subsequently, dose program das for higher once the biomarker
manufacturing non-CDMO-dependent IIIA Cleveland I'll we await data, out being is of remind product our owned ABO-XXX made. these for that facility, MPS As you wholly commercial-grade
dependent AAV IIIB EB-XXX Center experience of Elisa our from highly and when owned production 'XX. for Our transferable to program, in course, we MPS data fully in if Linton will manufacture decide be
Finally, I'll update and give a open the brief up it group to for questions. I'll preclinical,
invented As unmet gene highest Abeona conducted undisclosed in novel identity represent AAV previously Abeona we eye and with fully X,XXX in preclinical needs. indications. XX,XXX therapy as continues our alone partnered the This capsids These about focused indications capsids integrated noted, high of opportunities with the unmet on including need. company research end-to-end our eye to a U.S. patients X
[Technical Difficulty]
